This inventor holds 2 USPTO granted patents. Top assignee: Florida International University. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023-2025
Title: Manuel Perez: Innovator in Stem Cell Exosome Technology
Introduction
Manuel Perez is a notable inventor based in Miami, FL, who has made significant contributions to the field of regenerative medicine. He holds 2 patents that focus on the production and application of stem cell-derived exosomes, which have the potential to revolutionize treatments for degenerative diseases.
Latest Patents
One of Manuel Perez's latest patents is titled "Systems and methods for producing injectable enhanced stem cell exosomes, improved exosomes and methods of use." This patent pertains to a non-living biological product, specifically exosomes derived from stem cells that can aid in restoring heart function. The invention utilizes a fluid-induced shear stress mechanical stimulation process to augment both the quantity and quality of exosomes produced from stem cells. These exosomes serve as therapeutic agents for the regenerative repair of diseases, particularly those affecting heart tissues. The patent also outlines compositions comprising these exosomes and methods for treating degenerative diseases through their administration.
Career Highlights
Manuel Perez is affiliated with Florida International University, where he continues to advance research in the field of stem cell technology. His work is pivotal in exploring innovative solutions for medical challenges, particularly in regenerative medicine.
Collaborations
Some of his notable coworkers include Sharan D Ramaswamy and Yih-Mei Lin, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Manuel Perez's work in stem cell exosome technology exemplifies the potential of innovative medical solutions to address critical health issues. His patents reflect a commitment to advancing regenerative medicine and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
